Ten Recent Landmark Trials Across Oncology - Dr Vidit Kapoor

Written by Dr Vidit Kapoor Published On 2024-02-10T13:06:36+05:30 | Updated On 10 Feb 2024 1:06 PM IST

Ten Recent Landmark Trials Across Oncology - Dr Vidit Kapoor

The field of Oncology has witnessed a transformative journey over the last decade, marked by groundbreaking discoveries and advancements that continue to redefine the way we approach and treat cancer.

As we navigate the ever-expanding landscape of oncology in 2023, several key trends and developments stand out in the management of both solid tumours and hematological malignancies.

The FLAURA 2 trial demonstrated that first line treatment with Osimertinib plus platinum based chemotherapy achieved a statistically significant and clinically meaningful improvement in progression free survival (PFS) by 38% compared to Osimertinib alone in patients with advanced or metastatic EGFR (Epidermal Growth Factor Receptor) mutated NSCLC.

This study supports the use of Osimertinib combined with platinum based chemotherapy as a new and promising first line treatment option in advanced/metastatic Non Small Cell Lung Cancer (NSCLC) with an EGFR mutation.

An updated analysis of the ADAURA trial, that analysed patients with surgically resected stage Ib to IIIa EGFR mutated NSCLC patients, revealed that there is a statistically significant Overall Survival (OS) Benefit with adjuvant Osimertinib.

This update enhances evidence in support of prescribing Osimertinib to patients with resected stage Ib to IIIa EGFR mutated NSCLC patients.

The PAPILLON trial showed that the use of amivantamab-chemotherapy resulted in superior efficacy with a significant prolongation of PFS as compared with chemotherapy alone as first line treatment of patients with advanced NSCLC with EGFR exon 20 insertions. At 18 months, PFS was reported in 31% of patients in the amivantamab-chemotherapy group and in 3% in the chemotherapy group.

The PROSPECT trial showed that in patients with locally advanced rectal cancer who were eligible for sphincter-sparing surgery, pre-operative chemotherapy with FOLFOX was non inferior to pre-operative chemoradiotherapy with respect to disease free survival suggesting that it may be possible for some patients with localized rectal cancer to forego pre-operative radiation therapy thus avoiding added toxicity.

In the KEYNOTE-A39 randomized phase III trial, Enfortumab Vedotin in combination with pembrolizumab (EV + P) significantly improved OS, reducing the risk of death by 53%, as compared to chemotherapy in patients with locally advanced/metastatic urothelial cancer.

Median OS was 31.5 months in the EV + P group versus 16.1 months in the chemotherapy group. [5] EV + P is a new standard of care treatment in the first line setting for locally advanced/metastatic urothelial cancer.

The LMS-04 trial demonstrated a statistically significant improvement in PFS with Doxorubicin plus Trabectedin as compared to Doxorubicin alone in the first line treatment setting in patients with unresectable or metastatic leiomyosarcoma which may be a new standard of care first line treatment in this patient population.

The SWOG S1826 study, a phase III randomized study of Nivolumab plus AVD (Adriamycin, Vinblastine and Dacarbazine) or Brentuximab Vedotin (BV) plus AVD in patients with newly diagnosed advanced stage Classical Hodgkin Lymphoma, showed a statistically significant superior PFS with reduced toxicity in the Nivolumab AVD group as compared to the BV ABD group.

The addition of nivolumab to AVD was associated with a 52% reduction in the risk of disease progression or death compared with BV AVD suggesting the use of Nivo AVD as a preferred standard of care in patients with advanced classical Hodgkin lymphoma.

The ZUMA-7 trial of patients with early relapsed or refractory large B-cell lymphoma who received CART (CD19 chimeric antigen receptor T cell therapy) with Axi-cel (Axicabtagene Ciloleucel) versus standard of care (chemoimmunotherapy +/- autologous stem cell transplant) resulted in a significantly longer median OS with Axi-cel (not reached) as compared to standard of care (31 months).

Similarly, the TRANSFORM trial showed significant improvements in event free survival, complete response rates and PFS with Liso-cel (lisocabtagene maraleucel) CART as a second line therapy in early relapsed/refractory large cell lymphoma. These results support the use of CART in patients with early relapsed or refractory large B cell lymphoma wherever available and possible.

In the ECOG-ACRIN E1910 Randomized phase III trial, the addition of Blinatumomab to consolidation chemotherapy resulted in a significantly better OS in patients with newly diagnosed B-lineage Acute Lymphoblastic Leukemia who were MRD (minimal residual disease) negative after intensive induction chemotherapy.

This result expands the use of blinatumomab to MRD negative patients in addition to MRD positive patients.

References

[1] Planchard D et al; FLAURA2 Investigators. Osimertinib with or without Chemotherapy in EGFR-Mutated Advanced NSCLC. N Engl J Med. 2023 Nov 23. PMID: 37937763.

[2] Tsuboi Met et al; ADAURA Investigators. Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. N Engl J Med. 2023 Jul 13; PMID: 37272535.

[3] Zhou C et al; PAPILLON Investigators. Amivantamab plus Chemotherapy in NSCLC with EGFR Exon 20 Insertions. N Engl J Med. 2023 Oct 21. PMID: 37870976.

[4] Deborah Schrag et al; Alliance N1048; Preoperative Treatment of Locally Advanced Rectal Cancer; Journal of Clinical Oncology 2023 41:17_suppl, LBA2

[5] TB Powles at al; Keynote A39; Open label, randomized phase III study of Enfortumab Vedotin in combination with Pembrolizumab (EV + P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma; Annals of Oncology; Oct 2023

[6] Pautier P et al; Doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin alone as first-line therapy for metastatic or unresectable leiomyosarcoma (LMS-04): a randomised, multicentre, open-label phase 3 trial. Lancet Oncol. 2022. PMID: 35835135.

[7] Alex Herrera et al; SWOG S1826, a randomized study of nivolumab AVD vs Brentuximab AVD (BV AVD) in advanced stage (AS) Classic Hodgkin Lymphoma (HL); Journal of Clinical Oncology 2023 41:17_suppl, LBA4

[8] Westin JR et al; ZUMA-7 Investigators; Kite Members. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. N Engl J Med. 2023 Jul 13. PMID: 37272527.

[9] Kamdar M et al; TRANSFORM Investigators. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): Lancet. 2022 Jun 18; PMID: 35717989.

[10] Mark R. Litzow et al; Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial. Blood 2022; 140 (Supplement 2): LBA–1.

Disclaimer: The views expressed in this article are of the author and not of Medical Dialogues. The Editorial/Content team of Medical Dialogues has not contributed to the writing/editing/packaging of this article.

Dr Vidit Kapoor

Dr Vidit Kapoor, MBBS, Residency (Internal Medicine), Fellowship (Medical Oncology and Hematology), is an Assistant Professor at Amrita Hospital, Faridabad. Dr Vidit Kapoor has rich experience of 10 years working in a multidisciplinary set-up with expertise in the spheres of Solid Tumour Oncology: Breast cancer, Lung cancer, Liver and Gall bladder cancer, Pancreatic cancer, Esophageal and Gastric cancer, Colorectal cancer, Prostate cancer, Cervix and Ovarian cancer, Kidney cancer, Head and Neck Cancer, Sarcomas and others and Hematological malignancies like Lymphomas, Leukemias, Myelomas, Chemotherapy, Immunotherapy, Targeted Therapy and Precision Oncology.